Spanish biotech company Minoryx Therapeutics, which develops treatments for orphan diseases affecting the central nervous system, has just announced the creation of a subsidiary in Gosselies Biopark, in Wallonia.
Last September, a group of Belgian investors led by Fund+, together with public investment funds SFPI, SRIW and Sambrinvest, injected 21.3 million euros into the capital of Minoryx Therapeutics, a Spanish biotech firm that develops treatments for orphan diseases affecting the central nervous system.
Following this investment, Minoryx will set up a subsidiary in Gosselies Biopark and use the local biotech ecosystem for researching and developing its MIN-102 molecule for new orphan indications.
The MIN-102 is in phase II/III clinical trials for the treatment of adrenomyeloneuropathy (a form of leukodystrophy that destroys the central nervous system) and patients were recruited earlier than planned. The trial is being carried out in seven European countries and three American States. The results of the trial are expected at the end of 2020.
Marc Martinell, CEO of Minoryx
We are delighted to develop our activities in Belgium, enjoy local experience in the development of biotechnology companies and establish contacts with public and private Belgian investors.
The company welcomed top level Belgian investors during its recent series B financing round of 21.3 million euros, giving it access to an attractive biotech ecosystem and strengthening its growth.
Founded in 2011 and based in Mataró, near Barcelona, Minoryx has already raised a total of 50 million euros in capital, mainly from international investment funds such as Roche Venture Fund, Ysios Capital, Kurma Partners, Chiesi Ventures and Caixa Capital Risc.